Original Article
Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial Infarction
N Engl J Med 2006; 355:1093-1104September 14, 2006
- Abstract
Background
Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation.
Methods
We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel–related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers.
Results
The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3% vs. 14.3%, P=0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6% and 13.4%, respectively; P<0.001). There was no significant difference between the two groups in the rate of death (2.3% and 2.2%, respectively; P=1.00), reinfarction (1.1% and 1.4%, respectively; P=1.00), or stent thrombosis (3.4% and 3.6%, respectively; P=1.00). The degree of neointimal proliferation, as assessed by the mean (±SD) in-stent late luminal loss, was significantly lower in the sirolimus-stent group (0.14±0.49 mm, vs. 0.83±0.52 mm in the uncoated stent group; P<0.001).
Conclusions
Among selected patients with acute myocardial infarction, the use of sirolimus-eluting stents significantly reduced the rate of target-vessel revascularization at 1 year. (ClinicalTrials.gov number, NCT00232830.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Actuarial Rate of Survival Free from Target-Vessel Failure among Patients Who Received Either a Sirolimus-Eluting Stent or an Uncoated Stent.Article Activity
- Article
The use of sirolimus-eluting coronary-artery stents significantly reduces the incidence of restenosis after percutaneous coronary intervention (PCI), as compared with the use of uncoated stents.1-3 However, most randomized trials evaluating sirolimus-eluting stents have excluded patients with acute myocardial infarction with ST-segment elevation. Small series of patients with acute myocardial infarction have shown that the implantation of a sirolimus-eluting stent is associated with a low rate of restenosis.4,5 In the Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent vs. Abciximab and Bare-Metal Stent in Myocardial Infarction (STRATEGY) trial, the use of sirolimus-eluting stents reduced cardiovascular events, as compared with the use of uncoated stents, in a small group of patients undergoing primary PCI. However, the design of the trial specified the use of different glycoprotein IIb/IIIa inhibitors in each of the two groups to mitigate the greater cost of the drug-eluting stents, which raised the possibility that the benefit was influenced by the specific antiplatelet regimen.6
We therefore designed a prospective, randomized, multicenter trial comparing the effectiveness of sirolimus-eluting stents with that of uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation.
Methods
Enrollment and Assignment of Patients
We enrolled patients at 48 centers in 15 countries to participate in the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON). The study protocol was approved by the ethics committee at each participating institution and was conducted according to the principles of the Declaration of Helsinki. All patients gave written informed consent before enrollment. The study was conducted from October 2003 to October 2005.
Patients were eligible for the trial if their symptoms began less than 12 hours before catheterization and if the electrocardiogram showed ST-segment elevation (at least 1 mm in two or more standard leads or at least 2 mm in two or more contiguous precordial leads). Clinical criteria for exclusion included the administration of fibrinolytic agents for the index infarction, overt acute heart failure, a previously documented left ventricular ejection fraction of less than 30%, previous myocardial infarction, and an estimated life expectancy of less than 12 months.
Diagnostic Angiography and Primary Intervention
Patients were premedicated with aspirin (at least 100 mg) and unfractionated heparin (5000 to 10,000 IU). A loading dose of 300 mg of clopidogrel was administered either before or immediately after PCI. Coronary angiography was performed through the femoral or radial artery with the use of standard techniques.
Selection and Randomization
The trial protocol required visualization of the culprit lesion before randomization, in order to determine whether the angiographic criteria for inclusion or exclusion were met. Randomization was therefore performed either immediately after coronary angiography if the infarct-related vessel was spontaneously patent or after reestablishing coronary-artery blood flow by the placement of a guidewire or by balloon angioplasty.
Criteria for angiographic exclusion included previous PCI of the infarct-related vessel, excessive tortuosity or calcification, ostial or multiple lesions, massive thrombus in the infarct-related artery, bifurcation or left main coronary-artery disease, and severe multivessel disease requiring surgical revascularization. Patients were finally included and randomly assigned to a treatment group if the target lesion had a maximum length of 30 mm and was located in a native coronary artery with a reference-vessel diameter of 2.25 mm to 3.50 mm.
Random assignments to the treatment groups were generated in blocks of four or six and were distributed in sealed envelopes to each participating center. Patients were randomly assigned to the groups in a 1:1 ratio. Patients received either a sirolimus-eluting stent (Cypher or Cypher Select, Cordis, Johnson & Johnson) or any commercially available uncoated stent. Patients, but not investigators, were unaware of the treatment assignment.
Stent Implantation
Direct implantation of a stent without previous balloon angioplasty was allowed if the culprit lesion was adequately visualized either spontaneously or after guidewire placement. In the case of insufficient stent expansion, the stent was dilated after placement with another angioplasty balloon that was shorter than the total length of the stent. Oversizing and additional high-pressure dilation after the initial procedure were not recommended. If more than one stent was implanted, the same type of stent (sirolimus-eluting or uncoated) was recommended. Intervention in noninfarct-related arteries during the initial procedure was discouraged.
Heparin was administered throughout the procedure in order to maintain an activated clotting time of 250 seconds or longer. Administration of platelet glycoprotein IIb/IIIa–receptor inhibitors was left to the investigator's discretion.
Follow-up
Clinical follow-up was performed at 30 days and at 6 and 12 months after the procedure. Combined antiplatelet therapy included daily administration of aspirin (100 mg) and either clopidogrel (75 mg) or ticlopidine (250 mg). Dual antiplatelet therapy was recommended for at least 6 months, and aspirin therapy was recommended indefinitely. Noninvasive testing to assess for evidence of ischemia was recommended before repeated revascularization. Patients were unaware of their treatment assignments throughout the follow-up period.
Angiographic follow-up at 8 months was planned for 200 patients at 12 centers. In these selected centers, consecutive patients were enrolled in the angiographic substudy until the total number of patients reached 210.
Quantitative Coronary Angiography
Technicians at an independent angiographic core laboratory (BioImaging, Leiden, the Netherlands), who were unaware of treatment assignment, analyzed all angiographic images with the use of edge-detection techniques.7 Binary restenosis was defined as stenosis of more than 50% of the luminal diameter. Late luminal loss was calculated as the difference between the minimum luminal diameter immediately after the procedure and at 8 months. Flow in the infarct-related vessel was graded according to the Thrombolysis in Myocardial Infarction (TIMI) trial classification.8
Primary and Secondary End Points
The primary end point of the study was target-vessel failure, defined as the composite of target-vessel revascularization, recurrent infarction, or target-vessel–related death at 1 year. The clinical events committee reviewed and adjudicated all serious clinical events, including stent thrombosis.
Target-vessel revascularization was defined as repeated PCI or bypass grafting of the target vessel, driven by clinical symptoms of myocardial ischemia, a positive stress test, electrocardiographic evidence of ischemic changes at rest attributable to the target vessel, or an in-lesion stenosis of more than 70% of the reference luminal diameter by visual estimate.
Recurrent infarction was defined as the recurrence of clinical symptoms or the occurrence of electrocardiographic changes accompanied by a new elevation in levels of creatine kinase, creatine kinase MB enzyme, or both. The level of creatine kinase required for the diagnosis of reinfarction depended on the interval from the index infarction: the creatine kinase level had to be at least 1.5 times the previous value if new symptoms appeared within 48 hours and at least 3 times the upper limit of normal if new symptoms appeared after 48 hours.
Death from cardiac causes included death from acute myocardial infarction, cardiac perforation, or pericardial tamponade; an arrhythmia or conduction abnormality; complications of the interventional procedure at baseline; stroke (including bleeding) within 30 days after the procedure or in connection with the procedure; and all deaths that could not be clearly attributed to a noncardiac cause.
The secondary end points of the trial included the rate of successful treatment of the lesion, defined by residual stenosis of less than 50% of the reference luminal diameter on quantitative coronary analysis and a TIMI flow grade of 3, and in-stent late luminal loss on quantitative coronary analysis at 8 months.
Definition of Stent Thrombosis
Stent thrombosis was classified as acute if it occurred within 24 hours after the index procedure, subacute if it occurred between 1 and 30 days, and late if it occurred after 30 days. Acute and subacute stent thrombosis were defined as angiographic proof of vessel occlusion, any recurrent Q-wave myocardial infarction in the territory of the stented vessel, or any death from cardiac causes. Late stent thrombosis was defined as any recurrent myocardial infarction with angiographic proof of vessel occlusion.
Study Design and Administration
Our study was proposed to the industry sponsor by four of the academic investigators: Drs. Henry, Spaulding, Teiger, and Slama. The same investigators wrote the final version of the protocol in collaboration with the industry sponsor, and the steering committee approved the design. Dr. Spaulding designed the statistical-analysis plan in collaboration with the sponsor.
Data were collected with the use of an electronic case-report form through a secured Internet-based Web site. A clinical research organization (Hesperion, Allschwil, Switzerland) performed all study monitoring, data management, and statistical analysis. The industry sponsor had no direct role in the collection or analysis of data. The steering committee had unrestricted access to the data and made all decisions about publication independently of the sponsor. Dr. Spaulding assumes overall responsibility for the integrity of the data, the accuracy of the data analyses, and the completeness of the material reported.
Statistical Analysis
The planned enrollment of 700 patients provided a statistical power of 80% to detect a 47% reduction in the rate of the primary end point at 1 year (from 17% in the uncoated-stent group to 9% in the sirolimus-stent group) with a 5% rate of false positive results in a two-sided test. The estimated enrollment for the angiographic substudy was based on an assumed in-stent late luminal loss of 0.43 mm in the sirolimus-stent group and 0.76 mm in the uncoated-stent group at 8 months, with an SD of 0.7 mm for both groups.2,9 After correction for loss to follow-up, we estimated that the enrollment of 200 patients provided 80% power with a false positive rate of 5% in a two-sided test.
All analyses were based on the intention to treat. The differences between the treatment groups were evaluated by analysis of variance or Wilcoxon rank-sum scores for continuous variables, if appropriate. Fisher's exact test was used for the analysis of categorical variables. The rate of survival free from target-vessel failure during the 1-year follow-up period was analyzed by the Kaplan–Meier method, and the difference in survival curves between the groups was assessed with the log-rank test. To test whether initial differences between the two treatment groups influenced the difference in outcome, multiple logistic-regression analysis was performed, controlling for all variables that were found to be significantly different at baseline. All statistical analyses were performed with the use of SAS software, version 8.2 (SAS Institute), and all reported P values are two-sided.
Results
Study Patients
Between October 2003 and September 2004, 2019 patients were screened and 715 were randomly assigned to the two treatment groups (356 to the sirolimus-stent group and 359 to the uncoated-stent group) (Figure 1Figure 1
Enrollment and Outcomes.). The most frequent reason for exclusion was fibrinolytic therapy for the index infarction. After randomization and treatment with the assigned stent, one patient in the sirolimus-stent group and two in the uncoated-stent group withdrew their consent to participate in the study.Baseline Characteristics and Medications Used
Patients in the uncoated-stent group were slightly older and had a higher rate of previous PCI involving a nontarget coronary vessel, a lower rate of culprit lesions in the left anterior descending coronary artery, and a higher rate of triple-vessel disease (Table 1Table 1
Baseline Characteristics of the Patients.). In both groups, the median time from the onset of chest pain to hospital admission was less than 4 hours, and the median interval between arrival at the hospital and inflation of the balloon catheter was 60 minutes. The rate of use of glycoprotein IIb/IIIa–receptor inhibitors and the specific agents used did not vary significantly between the two groups (Table 2Table 2
Procedural Results and Use of Medication during the Trial.).Clinical Outcome at 1 Year
The primary end point of the study — target-vessel failure at 1 year — occurred in 7.3% of patients in the sirolimus-stent group and in 14.3% in the uncoated-stent group (P=0.004) (Table 3Table 3
Clinical Events at 1 Year.). This difference was due almost entirely to significant differences in the rates of target-vessel revascularization. There was no significant difference between the sirolimus-stent group and the uncoated-stent group in the rates of death (2.3% and 2.2%, respectively; P=1.00), recurrent myocardial infarction (1.1% and 1.4%, respectively; P=1.00), or in-stent thrombosis (3.4% and 3.6%, respectively; P=1.00). The actuarial rate of survival free from target-vessel failure was significantly higher in the sirolimus-stent group than in the uncoated-stent group (92.5% vs. 85.2%, P<0.001) (Figure 2Figure 2Actuarial Rate of Survival Free from Target-Vessel Failure among Patients Who Received Either a Sirolimus-Eluting Stent or an Uncoated Stent.).Multivariate analysis of the primary end point was performed to control for all significant variables in Table 1 and Table 2, including the use of clopidogrel, at 6 months. On the basis of this adjusted analysis, patients in the sirolimus-stent group were less than half as likely as those in the uncoated-stent group to have target-vessel failure (odds ratio, 0.41; P=0.001).
Angiographic Follow-up Study
Of the 210 patients included in the angiographic substudy, 174 underwent angiography at 8 months (82.8%) and 170 had qualifying angiograms (81.0%) (Figure 1 and Table 4Table 4
Angiographic Measurements Obtained at the Time of the Index Procedure and at Follow-up at 8 Months). Patients in the angiographic study, as compared with those not in the study, tended to have higher rates of target-vessel failure (13.3% vs. 9.8%, P=0.19) and revascularization (12.4% vs. 8.4%, P=0.12), although these differences were not significant. However, the reduction in target-vessel failure in the sirolimus-stent groups was similar whether or not follow-up angiography was performed. At 8 months, sirolimus-eluting stents, as compared with uncoated stents, were associated with significant mean reductions in in-stent late luminal loss (0.14±0.49 mm vs. 0.83±0.52 mm, P<0.001) and in-stent restenosis (3.5% vs. 20.3%, P=0.001).Discussion
In our trial, the use of sirolimus-eluting stents during primary PCI was associated with a reduction in the incidence of target-vessel failure at 1 year, as compared with the use of uncoated stents (7.3% vs. 14.3%, P=0.004). This difference was mainly driven by a reduction in the incidence of target-vessel revascularization. The results of the angiographic follow-up study suggest that the mechanism of benefit involves the suppression of neointimal proliferation among patients receiving sirolimus-eluting stents. The average in-stent late luminal loss in the sirolimus-stent group in our study was similar to that in previous studies of patients undergoing elective procedures.2,3,10
Rates of stent thrombosis were similar in the sirolimus-stent and uncoated-stent groups (3.4% and 3.6%, respectively; P=1.00). These rates were higher than those in previous studies. Reported rates of stent thrombosis vary according to the clinical presentation and the definition used. In recent trials of sirolimus-eluting stents that included only elective cases and used the same definition that we used in our trial, cumulative rates of stent thrombosis ranged from 0 to 1.1%.1-3,10 A higher rate (2.0%) was reported for sirolimus-eluting stents in the Sirolimus-Eluting Stent Compared with Paclitaxel-Eluting Stent for Coronary Revascularization (SIRTAX) trial (a comparison of the Cypher stent and the Taxus stent), which included both patients with and those without acute myocardial infarction.11 Elsewhere in this issue of the Journal, Laarman et al.12 report the results of the Paclitaxel-Eluting Stent versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation (PASSION) trial, which showed a lower overall rate of stent thrombosis (1%) than did our study. However, angiographic proof was required for the diagnosis of stent thrombosis, and adjudication was not performed by an independent clinical events committee. The rates of stent thrombosis in the STRATEGY trial were 0% in the group receiving sirolimus-eluting stents and 3% in the group receiving uncoated stents.6 The 1-month rate of stent thrombosis in trials and registries with uncoated stents in acute myocardial infarction ranges from 0.9 to 4.3%.9,13-19
Procedural factors may have contributed to in-stent thrombosis in our study. Suboptimal procedural regimens of aspirin and heparin were allowed, with minimal aspirin doses of 100 mg and a minimal activated clotting time of 250 seconds, in contrast to recent recommendations.20 Furthermore, incomplete stent deployment favoring in-stent thrombosis cannot be ruled out, since the mean residual stenosis after the procedure was higher in both groups than that in previous studies.1,2 Finally, our definition of acute and subacute thrombosis was broad and included both death and repeated myocardial infarction if angiographic proof of stent patency was not available. In contrast, the definition of late thrombosis required angiographic proof of stent thrombosis. Accordingly, 30-day rates of stent thrombosis may have been overestimated and those of late thrombosis underestimated.
In comparison with our study, trials and registries of primary PCI in patients with acute myocardial infarction with ST-segment elevation have reported lower rates of repeated revascularization. In fact, our rates are similar to those of previous studies in patients in stable condition.9,13-18 This finding may be related to the effect of angiographic follow-up in a subgroup of patients, since revascularization rates tended to be higher among patients undergoing follow-up angiography. Nevertheless, the significant difference in the rates of target-vessel failure was maintained in the subgroup of patients without angiographic follow-up. Furthermore, noninvasive testing was performed on a routine basis at 6 months, an approach that may have led to an increased rate of ischemia-driven revascularization. Another factor may have been the speed of intervention (median interval from arrival at the hospital to inflation of the balloon catheter, 60 minutes), which left patients with a relatively large amount of viable myocardium at risk. In the PASSION trial, the revascularization rate in the group receiving uncoated stents was surprisingly low, and the incidence of the primary end point was lower than the expected rate. The enrollment of fewer patients with diabetes and more patients with larger target vessels in the PASSION trial may account for these differences.12
Our results cannot be generalized to all patients with acute myocardial infarction, since high-risk patients were excluded. Furthermore, our findings cannot be extended to other drug-eluting stents. Despite adjudication of events by an independent clinical events committee, the single-blind study design is an obvious limitation. This is especially true since the beneficial effect of sirolimus-eluting stents on the primary end point was almost entirely due to a reduction in target-vessel revascularization, which was performed by investigators who were not specifically blinded to the study assignment of each patient. Although an analysis that was adjusted for differences between treatment groups in baseline characteristics did not change the findings, other variables might have influenced them. Finally, an assessment of long-term safety and durability will require longer follow-up of a larger cohort of patients.
In summary, in our study, patients with acute myocardial infarction with ST-segment elevation who received sirolimus-eluting stents had a significantly lower rate of target-vessel failure than those who received uncoated stents. This difference was due almost entirely to a significant reduction in the rate of target-vessel revascularization. An angiographic follow-up study showed significant reductions in in-stent restenosis and in-stent late luminal loss.
Supported by Cordis, Johnson & Johnson.
Drs. Spaulding, Henry, Teiger, Beatt, Carrié, Slama, Varenne, and Bode report having received consulting or lecture fees from Cordis, Johnson & Johnson; and Dr. Beatt, grant support from Cordis, Johnson & Johnson. Drs. Cebrian, Stoll, and Snead are full-time employees of Cordis, Johnson & Johnson, and Drs. Stoll and Snead report holding equity interest in the company. No other potential conflict of interest relevant to this article was reported.
We are indebted to the patients who agreed to participate in the study; to the study coordinators, technicians, and nurses in the participating centers; and to Rita Dalal and Lorraine Wheeler for their editorial assistance.
Source Information
From Assistance Publique–Hôpitaux de Paris (AP–HP) Cochin Hospital, Paris 5 Medical School Rene Descartes University and INSERM U780, Paris (C.S., O.V.); AP–HP Lariboisiere Hospital, Paris 7 Medical School University Denis Diderot, Paris (P.H.); AP–HP Henri Mondor Hospital, Paris 12 Medical School, Créteil (E.T.); Hospital Rangueil, Toulouse (D.C.); and AP–HP Antoine Béclère Hospital, Paris 12 Medical School Paris Sud University, Clamart (M.S.S.) — all in France; Mayday University Hospital, London (K.B.); Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia (E.B.), and Azienda Universitaria Ospedaliera Careggi, Florence (M.M.) — both in Italy; Semmelweis University, Budapest (B.M.); Pauls Stradins University Hospital, Riga, Latvia (A.E.); Cordis (Johnson & Johnson), Waterloo, Belgium (A.C., H.-P.S.) and Warren, NJ (D.B.S.); and the University of Freiburg, Freiburg, Germany (C.B.).
Address reprint requests to Dr. Spaulding at Cochin Hospital, 27 rue du Faubourg St. Jacques, 75014 Paris, or at christian.spaulding@cch.ap-hop-paris.fr.
Members of the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) are listed in the Appendix.
Appendix
The following investigators and institutions participated in the TYPHOON study: Steering Committee: C. Spaulding, C. Bode, E. Bramucci, P. Henry, E. Teiger, D. Carrie, M. Slama, K. Beatt; Sponsor: Cordis, Warren, NJ — D. Donohoe (medical director), D. Snead, R. Dalal, S. Sun; Cordis, Waterloo, Belgium — H.-P. Stoll (program director), A. Cebrian (program coordination), L. Wheeler; Data and Safety Monitoring Board: B. Meier, Switzerland; B. Lancelin, France; J.-F. Neumann, Germany; Clinical Events Committee: A. Caspi (chair), Israel; G. Maurer, Austria; S. Cook, Switzerland; Data Management and Monitoring: Hesperion, Clinical Development Services, Allschwil, Switzerland — V. Charlon (director); C. Berge; P. Rush; Electronic Data Capture: PPD GlobalView Web Services, New Hope, MN; Core Angiographic Laboratory: Bio Imaging Technologies, Leiden, the Netherlands — A. Van Weert (director); Clinical Sites: Royal Perth Hospital, Perth, Australia — R. Clugston, M. Bonner; Hôpital Cantonal de Genève, Geneva — E. Camenzind, N. Masson; Nemocnice Ceske, Budejovice, Czech Republic — L. Pesl; Poruba School of Medicine, Poruba, Czech Republic — R. Stipal, L. Pleva; Medizinische Universitätsklinik Freiburg, Freiburg, Germany — C. Bode, M. Zehender, S. Richter; Universitätskliniken des Saarlandes, Homburg Saar, Germany — G. Nickenig, N. Werner; Medizinische Klinik und Poliklinik Johannes-Gutenberg-Universität, Mainz, Germany — F. Post; Københavns Amtssygehus Gentofte, Hellerup, Denmark — U. Abildgaard, A. Galloe; Virgen de la Arrixaca, Murcia, Spain — M. Valdés, E. Pinar; Hôpital Européen Georges Pompidou, Paris — N. Danchin; Institut Mutualiste Montsouris, Paris — A. Dibie, F. Larrazet, F. Philippe; Clinique du Millénaire, Montpellier, France — X. De Boisgelin, G. Levy; Hôpital Lariboisiere, Paris — P. Henry, G. Sideris, R. Fressonnet; Hôpital Bichat, Paris — J.-M. Juliard, P. Aubry; Hôpital Tenon, Paris — P. Michel, E. Garbarz; Hôpital Béclère, Clamart, France — M. Slama, P. Colin; Hôpital Cochin, Paris — C. Spaulding, O. Varenne; Henri Mondor Hospital, Paris — E. Teiger, J. Dubois-Randé, S. Champagne; Centre Hospitalier Universitaire Toulouse–Hôpital Rangueil, Toulouse, France — D. Carrié, J. Roncalli, J. Cahuzac; Clinique Les Fleurs, Marseille, France — P. Commeau, P. Barragan; Hôpital Guillaume et René Laennec, Centre Hospitalier Universitaire Nord, St. Herblain, France — P. Guerin, A. Tirouvanziam; Clinique St. Augustin, Bordeaux, France — O. Darremont, J. Leymarie; Centre Hospitalier Régional d'Orleans–Hôpital de la Source, Orleans, France — O. Dibon; Clinique Pasteur, Toulouse, France — J. Fajadet, B. Farah, B. Assoun; Centre Cardiologique du Nord, Saint Denis, France — P. Guyon, B. Chevalier; Clinique Victor Pauchet, Amiens, France — A. Py, E. Dadez; Centre Hospitalier Universitaire de Rennes, Rennes, France — H. Le Breton, M. Bedossa; Centre Hospitalier Universitaire Mulhouse, Mulhouse, France — L. Jacquemin, R. ElBelghit; Institut Hospitalier Jacques Cartier, Massy, France — M. Morice, T. Lefèvre; Centre Hospitalier Universitaire Avignon, Avignon, France — M. Pansieri, M. Metge; Clinique de la Casamance, Aubagne, France — B. Valeix; Clinique Médico-Chirurgicale Les Fontaines, Melun, France — P. Dupouy, E. Aptecar; Cardiovascular Center, Semmelweis University, Budapest, Hungary — B. Merkely, G. Szabó; Wolfson Medical Center, Holon, Israel — Y. Rozenman, V. Witzling; Assaf Harofeh Medical Center, Zrifin, Israel — R. Krakover, I. Zyssman; Soroka Medical Center, Beer Sheva, Israel — R. Ilia, C. Cafri; Souraski Medical Center, Tel Aviv, Israel — H. Miller, A. Finkelstein; Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy — E. Bramucci, M. Ferlini, U. Canosi; San Filippo Neri Hospital, Rome — G. Richichi, V. Pasceri; Azienda Ospedale Luigi Sacco, Milan — P. Viecca; Azienda Ospedaliera Careggi, Florence, Italy — M. Margheri, C. Giglioli; Pauls Stradins University Hospital, Riga, Latvia — A. Erglis; I. Narbute; University Medical Center Utrecht, Utrecht, the Netherlands — P. Stella; P. Elsman; Slaskie Centrum Chorób Serca, Zabrze, Poland — L. Poloński; Hospital Fernando Fonseca, Amadora, Portugal — P. Farto e Abreu; Hospital Garcia Orta, Almada, Portugal — H. Pereira; Hammersmith Hospital, London — K. Beatt; and Southampton General Hospital, Southampton, United Kingdom — K. Dawkins.
- References
References
1
Morice M-C ,Serruys PW ,Sousa JE , et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780
Full Text | Web of Science | Medline2
Moses JW ,Leon MB ,Popma JJ , et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323
Full Text | Web of Science | Medline3
Schofer J ,Schluter M ,Gershlick AH , et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099
CrossRef | Web of Science | Medline4
Saia F ,Lemos PA ,Lee CH , et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study. Circulation 2003;108:1927-1929
CrossRef | Web of Science | Medline5
Lemos PA ,Lee CH ,Degertekin M , et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41:2093-2099
CrossRef | Web of Science | Medline6
Valgimigli M ,Percoco G ,Malagutti P , et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-2117
CrossRef | Web of Science | Medline7
Serruys PW, Foley DP, de Feyter PJ, eds. Quantitative coronary angiography in clinical practice. Dordrecht, the Netherlands: Kluwer Academic, 1994.
8
The TIMI Study Group
Web of Science | Medline9
Grines CL ,Cox DA ,Stone GW , et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999;341:1949-1956
Full Text | Web of Science | Medline10
Morice MC ,Colombo A ,Meier B , et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904
CrossRef | Web of Science | Medline11
Windecker S ,Remondino A ,Eberli FR , et al. Sirolimus-eluting and paclitaxel-euting stents for coronary revascularization. N Engl J Med 2005;353:653-662
Full Text | Web of Science | Medline12
Laarman GJ ,Suttorp MJ ,Dirksen MT , et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113
Full Text | Web of Science | Medline13
Spaulding C ,Cador R ,Benhamda K , et al. One-week and six-month angiographic controls of stent implantation after occlusive and nonocclusive dissection during primary balloon angioplasty for acute myocardial infarction. Am J Cardiol 1997;79:1592-1595
CrossRef | Web of Science | Medline14
Stone GW ,Grines CL ,Cox DA , et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966
Full Text | Web of Science | Medline15
Maillard L ,Hamon M ,Khalife K , et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2000;35:1729-1736
CrossRef | Web of Science | Medline16
Antoniucci D ,Santoro GM ,Bolognese L ,Valenti R ,Trapani M ,Fazzini PF . A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234-1239
CrossRef | Web of Science | Medline17
Rodriguez A ,Bernardi V ,Fernandez M , et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Am J Cardiol 1998;81:1286-1291
CrossRef | Web of Science | Medline18
Saito S ,Hosokawa G ,Tanaka S ,Nakamura S . Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. Catheter Cardiovasc Interv 1999;48:262-268
CrossRef | Web of Science | Medline19
Monassier JP ,Hamon M ,Elias J , et al. Early versus late coronary stenting following acute myocardial infarction: results of the STENTIM I Study (French Registry of Stenting in Acute Myocardial Infarction). Cathet Cardiovasc Diagn 1997;42:243-248
CrossRef | Medline20
Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). (Available at http://www.acc.org/qualityandscience/clinical/guidelines/percutaneous/update/index.pdf.)
- Citing Articles (231)
Citing Articles
1
SUDHAKAR SATTUR, PAM ORSHAW, JUDY BOURA, KISHORE J. HARJAI. (2012) Long-Term Safety and Effectiveness of Drug-Eluting Stents Compared to Bare Metal Stents in ST Elevation Myocardial Infarction: Findings from the Guthrie Health Off-Label Stent (GHOST) Registry. Journal of Interventional Cardiologyno-no
CrossRef2
Ryota Sakurai, Tsukasa Inajima, Hideaki Kaneda, Ryozo Nagai, Hideki Hashimoto. (2012) Sirolimus-eluting stents reduce long-term mortality compared with bare metal stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized controlled trials. International Journal of Cardiology
CrossRef3
Lisette Okkels Jensen, Michael Maeng, Per Thayssen, Hans Henrik Tilsted, Christian Juhl Terkelsen, Anne Kaltoft, Jens Flensted Lassen, Knud Nørregaard Hansen, Jan Ravkilde, Evald Høj Christiansen, Morten Madsen, Henrik Toft Sørensen, Leif Thuesen. (2011) Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology
CrossRef4
Woong Chol Kang, Taehoon Ahn, Kyounghoon Lee, Seung Hwan Han, Eak Kyun Shin, Myung Ho Jeong, Jung Han Yoon, Jong Sun Park, Jang Ho Bae, Seung Ho Hur, Seung Woon Rha, Seok Kyu Oh, Doo Il Kim, Yangsoo Jang, Jae Woong Choi, Byung Ok Kim. (2011) Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 7:8, 936-943
CrossRef5
Manel Sabaté, Angel Cequier, Andrés Iñiguez, Antonio Serra, Rosana Hernández-Antolín, Vicente Mainar, Marco Valgimigli, Maurizio Tespili, Pieter den Heijer, Armando Bethencourt, Nicolás Vázquez, Salvatore Brugaletta, Bianca Backx, Patrick Serruys. (2011) Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention 7:8, 977-984
CrossRef6
, B. Scheller, B. Levenson, M. Joner, R. Zahn, V. Klauss, C. Naber, V. Schächinger, A. Elsässer. (2011) Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. Der Kardiologe
CrossRef7
Michael Mahmoudi, Cedric Delhaye, Ron Waksman. (2011) Safety and efficacy of drug-eluting stents and bare metal stents in acute coronary syndrome. Cardiovascular Revascularization Medicine 12:6, 385-390
CrossRef8
Joshua M. Stolker, David J. Cohen, Jason B. Lindsey, Kevin F. Kennedy, Neal S. Kleiman, Steven P. Marso. (2011) Mode of death after contemporary percutaneous coronary intervention: A report from the Evaluation of Drug Eluting Stents and Ischemic Events registry. American Heart Journal 162:5, 914-921
CrossRef9
João Brito, Manuel Almeida, Rui Campante Teles, Pedro Sousa, João Abecasis, Rita Calé, Pedro Gonçalves, Luís Raposo, Miguel Mendes. (2011) Outcomes of drug-eluting stents compared to bare-metal stents in ST-segment elevation acute myocardial infarction. Revista Portuguesa de Cardiologia 30:11, 813-819
CrossRef10
João Brito, Manuel Almeida, Rui Campante Teles, Pedro Sousa, João Abecasis, Rita Calé, Pedro Gonçalves, Luís Raposo, Miguel Mendes. (2011) Outcomes of drug-eluting stents compared to bare-metal stents in ST-segment elevation acute myocardial infarction. Revista Portuguesa de Cardiologia (English Edition) 30:11, 813-819
CrossRef11
So-Yeon Choi, Akiko Maehara, Ecaterina Cristea, Bernhard Witzenbichler, Giulio Guagliumi, Bruce Brodie, Mirle A. Kellett, Ovidiu Dressler, Alexandra J. Lansky, Helen Parise, Roxana Mehran, Gary S. Mintz, Gregg W. Stone. (2011) Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy). The American Journal of Cardiology
CrossRef12
Emilio Lorenzo, Giannignazio Carbone, Luigi Sauro, Alfredo Casafina, Michele Capasso, Rosario Sauro. (2011) Bare-Metal Stents Versus Drug-Eluting Stents for Primary Angioplasty: Long-Term Outcome. Current Cardiology Reports 13:5, 459-464
CrossRef13
Daria Mochly-Rosen, Kevin V. Grimes. (2011) Myocardial salvage in acute myocardial infarction - Challenges in clinical translation. Journal of Molecular and Cellular Cardiology 51:4, 451-453
CrossRef14
PEDRO BERALDO DE ANDRADE, MARDEN ANDRÉ TEBET, FELIPE SOUZA MAIA DA SILVA, MÔNICA VIEIRA ATHANAZIO DE ANDRADE, ANDRÉ LABRUNIE, LUIZ ALBERTO PIVA E MATTOS. (2011) Drug-Eluting Stents during ST-Segment Elevation Acute Myocardial Infarction: A Critical Analysis. Journal of Interventional Cardiology 24:5, 416-423
CrossRef15
Georgios Sideris, Sebastian Voicu, Jean Guillaume Dillinger, Victor Stratiev, Damien Logeart, Claire Broche, Benoit Vivien, Pierre-Yves Brun, Nicolas Deye, Dragos Capan, Mounir Aout, Bruno Megarbane, Frédéric J. Baud, Patrick Henry. (2011) Value of post-resuscitation electrocardiogram in the diagnosis of acute myocardial infarction in out-of-hospital cardiac arrest patients. Resuscitation 82:9, 1148-1153
CrossRef16
A. Schwindt, G. Pannuccio, K. Donas, G. Torsello. (2011) Wertigkeit der Drug-eluting Stents im Bereich der femorodistalen Arterien. Gefässchirurgie 16:5, 310-316
CrossRef17
Etienne Puymirat, Fabio Mangiacapra, Aaron Peace, Faisal Sharif, Micaela Conte, Jozef Bartunek, Marc Vanderheyden, William Wijns, Bernard de Bruyne, Emanuele Barbato. (2011) Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. American Heart Journal
CrossRef18
Giovanni Amoroso, Robert-Jan van Geuns, Christian Spaulding, Stephane Manzo-Silberman, Karl E. Hauptmann, René Spaargaren, Héctor M. García-García, Patrick W. Serruys, Stefan Verheye. (2011) Assessment of the safety and performance of the STENTYS self-expanding coronary stent in acute myocardial infarction: results from the APPOSITION I study. EuroIntervention 7:4, 428-436
CrossRef19
RHIDIAN J. SHELTON, KAMAL CHITKARA, RAVI SINGH, MICHA F. DORSCH, KATHRYN SOMERS, JAMES M. MCLENACHAN, JONATHAN M. BLAXILL, STEPHEN B. WHEATCROFT, DANIEL J. BLACKMAN, JOHN P. GREENWOOD. (2011) Three-Year Clinical Outcome with the Endeavor™ Zotarolimus-Eluting Stent in Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction: The Endeavor™ Primary PCI Study (E-PPCI). Journal of Interventional Cardiologyno-no
CrossRef20
Raffaele Piccolo, Salvatore Cassese, Gennaro Galasso, Roberta De Rosa, Carolina D’Anna, Federico Piscione. (2011) Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: A meta-analysis of randomized trials. Atherosclerosis 217:1, 149-157
CrossRef21
Edward L. Hannan, Zaza Samadashvili, Gary Walford, David R. Holmes, Alice K. Jacobs, Nicholas J. Stamato, Ferdinand J. Venditti, Samin Sharma, Icilma Fergus, Spencer B. King. (2011) Comparison of Outcomes for Patients Receiving Drug-Eluting Versus Bare Metal Stents for Non–ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology 107:9, 1311-1318
CrossRef22
Birgit Hailer, Christoph Naber, Bernd Koslowski, Peter van Leeuwen, Harald Schäfer, Thomas Budde, Rainer Jacksch, Georg Sabin, Raimund Erbel, . (2011) Gender-Related Differences in Patients With ST-Elevation Myocardial Infarction: Results From the Registry Study of the ST Elevation Myocardial Infarction Network Essen. Clinical Cardiology 34:5, 294-301
CrossRef23
Ajay J. Kirtane, Adriano Caixeta, Philippe Généreux, Rikesh Patel, Jeffrey W. Moses. 2011. Sirolimus and Paclitaxel Eluting Stent Clinical Studies. , 502-518.
CrossRef24
Neil Swanson, Anthony Gershlick. 2011. Primary and Rescue PCI in Acute Myocardial Infarction. , 242-261.
CrossRef25
Raul Moreno, Roberto Martin-Reyes, Santiago Jimenez-Valero, Angel Sanchez-Recalde, Guillermo Galeote, Luis Calvo, Ignacio Plaza, Jose-Luis Lopez-Sendon. (2011) Determining clinical benefits of drug-eluting coronary stents according to the population risk profile: A meta-regression from 31 randomized trials. International Journal of Cardiology 148:1, 23-29
CrossRef26
Alessandro Sciahbasi, Gianluca Pendenza, Enrico Romagnoli, Francesco Summaria, Roberto Patrizi, Valerio Lucci, Maria Benedetta Giannico, Maria Penco, Ernesto Lioy. (2011) The PREHAMI (PREsillion™ in high-risk acute myocardial infarction) registry. Catheterization and Cardiovascular Interventions 77:5, 608-614
CrossRef27
Asmir Syed, Itsik Ben-Dor, Yanlin Li, Sara Collins, Rebecca Torguson, Kohei Wakabayashi, Manuel Gonzalez, Gabriel Maluenda, Cedric Delhaye, Loic Belle, Michael Gaglia, Zhenyi Xue, Kimberly Kaneshige, Nelson Bernardo, Kenneth Kent, William Suddath, Lowell Satler, Augusto Pichard, Joseph Lindsay, Ron Waksman. (2011) Hybrid strategy of a bare metal stent combined with a drug-eluting stent versus exclusive drug-eluting stent implantation for multivessel percutaneous coronary intervention. EuroIntervention 6:9, 1085-1090
CrossRef28
Philip Urban, Alexandre Abizaid, Adrian Banning, Antonio L. Bartorelli, Ana Cebrian Baux, Vladimír Džavík, Stephen Ellis, Runlin Gao, David Holmes, Myung Ho Jeong, Victor Legrand, Franz-Josef Neumann, Maria Nyakern, Christian Spaulding, Stephen Worthley. (2011) Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. Journal of the American College of Cardiology 57:13, 1445-1454
CrossRef29
Hyun-Sook Kim, Jae-Hwan Lee, Seung-Whan Lee, Young-Hak Kim, Jae-Hyeong Park, Si-Wan Choi, Jin-Ok Jeong, In-Whan Seong, Kyoung-Suk Rhee, Jae-Ki Ko, Sang-Ho Jo, Young Jin Choi. (2011) Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. International Journal of Cardiology 147:2, 253-257
CrossRef30
Pow-Li Chia, Arul Earnest, Jimmy Lim. (2011) Biolimus-eluting biodegradable polymer-coated stent versus bare metal stent in acute ST-elevation and non-ST elevation myocardial infarction: Justification for biodegradable polymer-coated stent in acute coronary syndrome (JANICE) registry. Acute Cardiac Care 13:1, 43-47
CrossRef31
Alamgir MN Kabir, Amalan Selvarajah, Alexander M Seifalian. (2011) How safe and how good are drug-eluting stents?. Future Cardiology 7:2, 251-270
CrossRef32
David M. Martin, Fergal J. Boyle. (2011) Drug-eluting stents for coronary artery disease: A review. Medical Engineering & Physics 33:2, 148-163
CrossRef33
Artur Dziewierz, Zbigniew Siudak, Tomasz Rakowski, Ralf Birkemeyer, Waldemar Mielecki, Paweł Ranosz, Jacek S. Dubiel, Dariusz Dudek. (2011) Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clinical Research in Cardiology 100:2, 139-145
CrossRef34
Sandhir B. Prasad, Thomas David, Yuvaraj Malaiapan, James D. Cameron, Ian T. Meredith. (2011) Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: Rationale and safety. Catheterization and Cardiovascular Interventions 77:2, 193-200
CrossRef35
Robert W Yeh, Malini Chandra, Charles E McCulloch, Alan S Go. (2011) Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Medicine 9:1, 78
CrossRef36
W. Shim, A. Mehta, S. Y. Lim, G. Zhang, C. H. Lim, T. Chua, P. Wong. (2011) G-CSF for stem cell therapy in acute myocardial infarction: friend or foe?. Cardiovascular Research 89:1, 20-30
CrossRef37
Min Goo Lee, Myung Ho Jeong, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jin Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Ki Bae Seung, Seung Jung Park. (2011) Comparison of Paclitaxel-, Sirolimus-, and Zotarolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction and Metabolic Syndrome. Circulation Journal 75:9, 2120-2127
CrossRef38
Doo Sun Sim, Myung Ho Jeong, Youngkeun Ahn, Young Jo Kim, Shung Chull Chae, Taek Jong Hong, In Whan Seong, Jei Keon Chae, Chong Jin Kim, Myeong Chan Cho, Ki Bae Seung, Seung Jung Park, . (2011) Effectiveness of Drug-Eluting Stents versus Bare-Metal Stents in Large Coronary Arteries in Patients with Acute Myocardial Infarction. Journal of Korean Medical Science 26:4, 521
CrossRef39
S. Garg, M. Magro, P.W. Serruys. 2011. Drug-Eluting Stents. , 427-448.
CrossRef40
Rohit S. Loomba, Suraj Chandrasekar, Neil Malhotra, Rohit R. Arora. (2011) Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis. ISRN Cardiology 2011, 1-6
CrossRef41
Ki Hong Lee, Youngkeun Ahn, Nam Sik Yoon, Hyun Ju Yoon, Young Joon Hong, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2011) Are Drug-Eluting Stents Safer and More Effective Than Bare-Metal Stents in Patients With Acute Myocardial Infarction?. International Heart Journal 52:2, 78-83
CrossRef42
Kentaro Ejiri, Masaharu Ishihara, Kazuoki Dai, Takashi Miki, Ichiro Inoue, Takuji Kawagoe, Yuji Shimatani, Fumiharu Miura, Yasuharu Nakama, Takayuki Otani, Hiroki Ikenaga, Nozomu Oda, Masayuki Nakamura. (2011) Three-Year Follow-up of Sirolimus-Eluting Stents vs. Bare Metal Stents for Acute Myocardial Infarction. Circulation Journal
CrossRef43
ANGELA MIGLIORINI, RENATO VALENTI, GUIA MOSCHI, GUIDO PARODI, GIAMPAOLO CERISANO, PIERGIOVANNI BUONAMICI, NAZARIO CARRABBA, DAVID ANTONIUCCI. (2010) Predictor of Stent Thrombosis in Patients Treated with Turbostratic Carbon-Coated Stent Implantation for Acute Myocardial Infarction. Journal of Interventional Cardiology 23:6, 554-559
CrossRef44
Kenneth Morgan, Marie Leahy, Jeremy Butts, Kevin Beatt. (2010) The cost effectiveness of primary angioplasty compared to thrombolysis in the real world: one year results from West London. EuroIntervention 6:5, 596-603
CrossRef45
Xiao-hong Pan, Ying-xue Chen, Mei-xiang Xiang, Geng Xu, Jian-an Wang. (2010) A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients. Journal of Zhejiang University SCIENCE B 11:10, 754-761
CrossRef46
Masami Nishino, Shiro Hoshida, Masayuki Taniike, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Hitoshi Yamaguchi, Kenjiro Tanaka, Jun Tanouchi, Yoshio Yamada. (2010) Vulnerable disease may induce neointimal coverage after silorimus-eluting stent implantation. American Heart Journal 160:3, 564-569
CrossRef47
R. Gurvitch, J. Lefkovits, R.J. Warren, S.J. Duffy, D.J. Clark, D. Eccleston, B.P. Yan, C. Reid, A. Brennan, N. Andrianopoulos, A.E. Ajani. (2010) Clinical outcomes of drug-eluting stent use in patients with ST elevation myocardial infarction. International Journal of Cardiology 143:3, 283-288
CrossRef48
Srinivas Iyengar, LeRoy E Rabbani. (2010) Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: Drug-Eluting Stents or Bare Metal Stents?. American Journal of Therapeutics 17:5, 516-522
CrossRef49
Wail Nammas, Khaled Hossam. (2010) Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents. American Heart Journal 160:2, e13
CrossRef50
Alfredo E Rodriguez, Agustina Rodriguez-Granillo. (2010) Stent selection in patients with acute coronary syndromes and unstable coronary lesions. Interventional Cardiology 2:4, 545-557
CrossRef51
Scot Garg, Patrick W. Serruys. (2010) Coronary Stents. Journal of the American College of Cardiology 56:10, S1-S42
CrossRef52
Anne Kaltoft, Henning Kelbæk, Leif Thuesen, Jens Flensted Lassen, Peter Clemmensen, Lene Kløvgaard, Thomas Engstrøm, Hans E. Bøtker, Kari Saunamäki, Lars R. Krusell, Erik Jørgensen, Hans-Henrik Tilsted, Evald H. Christiansen, Jan Ravkilde, Lars Køber, Klaus F. Kofoed, Christian J. Terkelsen, Steffen Helqvist. (2010) Long-Term Outcome After Drug-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 56:8, 641-645
CrossRef53
Michael S. Lee, Pooya Bokhoor, Seung-Jung Park, Young-Hak Kim, Gregg W. Stone, Imad Sheiban, Giuseppe Biondi-Zoccai, Dario Sillano, Jonathan Tobis, David E. Kandzari. (2010) Unprotected Left Main Coronary Disease and ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 3:8, 791-795
CrossRef54
TATIANA BERLIN, ELIEZER ROZENBAUM, JOEL ARBEL, ORNA REGES, JACOB EREL, ISRAEL SHETBOUN, MORTON LEIBOVITCH, MORRIS MOSSERI. (2010) Six- and Twelve-Month Clinical Outcomes after Implantation of Prokinetic BMS in Patients with Acute Coronary Syndrome. Journal of Interventional Cardiology 23:4, 377-381
CrossRef55
Giuseppe Luca, Rosario Sauro, Attilio Varricchio, Michele Capasso, Tonino Lanzillo, Fiore Manganelli, Ciro Mariello, Francesco Siano, Giannignazio Carbone, Maria Rosaria Pagliuca, Giuseppe Rosato, Emilio Lorenzo. (2010) Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES. Journal of Thrombosis and Thrombolysis 30:2, 133-141
CrossRef56
Seung-Woon Rha, Yong-Jian Li, Kang-Yin Chen, Kanhaiya L. Poddar, Zhe Jin, Yoshiyasu Minami, Lin Wang, Qun Dang, Guang-Ping Li, Sureshkumar Ramasamy, Ji-Young Park, Cheol Ung Choi, Jin-Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong, Young Keun Ahn, Taek Jong Hong, Jong-Seon Park, Young Jo Kim, Seung Ho Hur, In Whan Seong, Jei Keon Chae, Myeong Chan Cho, Jang Ho Bae, Dong Hoon Choi, Yang Soo Jang, In Ho Chae, Hyo Soo Kim, Chong Jin Kim, Jung Han Yoon, Tae Hoon Ahn, Seung-Jea Tahk, Wook Sung Chung, Ki Bae Seung, Seung Jung Park. (2010) Response to the letter regarding the article “Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents”. American Heart Journal 160:2, e15-e16
CrossRef57
Nobuaki Suzuki, Ken Kozuma, Kengo Tanabe, Yuji Ikari, Toshiya Muramatsu, Takaaki Isshiki. (2010) Clinical and angiographic outcomes after bare metal stents implantation for the patients with acute ST-elevation myocardial infarction: insights from multicenter trials. Cardiovascular Intervention and Therapeutics 25:2, 98-104
CrossRef58
Jael Z. Atary, Bas L. van der Hoeven, Su San Liem, J. Wouter Jukema, Johanna G. van der Bom, Douwe E. Atsma, Marianne Bootsma, Katja Zeppenfeld, Ernst E. van der Wall, Martin J. Schalij. (2010) Three-Year Outcome of Sirolimus-Eluting Versus Bare-Metal Stents for the Treatment of ST-Segment Elevation Myocardial Infarction (from the MISSION! Intervention Study). The American Journal of Cardiology 106:1, 4-12
CrossRef59
Kazuoki Dai, Masaharu Ishihara, Ichiro Inoue, Takuji Kawagoe, Yuji Shimatani, Satoshi Kurisu, Yasuharu Nakama, Tatsuya Maruhashi, Eisuke Kagawa, Toshiyuki Aokage, Junichi Matsushita, Hiroki Ikenaga. (2010) Coronary angioscopic findings eight months after sirolimus-eluting stent implantation: a comparison between ST-elevation myocardial infarction and stable angina pectoris. EuroIntervention 6:2, 251-256
CrossRef60
Alban Dibra, Klaus Tiroch, Stefanie Schulz, Henning Kelbæk, Christian Spaulding, Gerrit J. Laarman, Marco Valgimigli, Emilio Lorenzo, Christoph Kaiser, Ilkka Tierala, Julinda Mehilli, Gianluca Campo, Leif Thuesen, Maarten A. Vink, Martin J. Schalij, Roberto Violini, Albert Schömig, Adnan Kastrati. (2010) Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clinical Research in Cardiology 99:6, 345-357
CrossRef61
Johann Auer, Alexander Leitner, Robert Berent, Gudrun Lamm, Elisabeth Lassnig, Gerald Krennmair. (2010) Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation. Atherosclerosis 210:2, 503-509
CrossRef62
Michael Mahmoudi, Ron Waksman. (2010) Drug-eluting stents for acute coronary syndromes: should the labeling be expanded?. Interventional Cardiology 2:3, 249-252
CrossRef63
Giulio Guagliumi, Vasile Sirbu, Hiram Bezerra, Giuseppe Biondi-Zoccai, Luigi Fiocca, Giuseppe Musumeci, Aleksandre Matiashvili, Nikoloz Lortkipanidze, Satoko Tahara, Orazio Valsecchi, Marco Costa. (2010) Strut Coverage and Vessel Wall Response to Zotarolimus-Eluting and Bare-Metal Stents Implanted in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 3:6, 680-687
CrossRef64
Zachary M. Gertz, Robert L. Wilensky. (2010) Local Drug Delivery for Treatment of Coronary and Peripheral Artery Disease. Cardiovascular Therapeuticsno-no
CrossRef65
Janette Greenhalgh, Juliet Hockenhull, Naveen Rao, Yenal Dundar, Rumona C Dickson, Adrian Bagust, Janette Greenhalgh. 2010. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. .
CrossRef66
Somjot S Brar, Gregg W Stone. (2010) Decision-making: stenting in acute myocardial infarction. Future Cardiology 6:3, 301-314
CrossRef67
Young-Hoon Jeong, Won-Jang Kim, Duk-Woo Park, Bong-Ryong Choi, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park. (2010) Serum B-type natriuretic peptide on admission can predict the ‘no-reflow’ phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction. International Journal of Cardiology 141:2, 175-181
CrossRef68
Youngjin Cho, Han-Mo Yang, Kyung-Woo Park, Woo-Young Chung, Dong-Joo Choi, Won-Woo Seo, Kyoung-Tae Jeong, Sung-Chul Chae, Myoung-Yong Lee, Seung-Ho Hur, Jei-Keon Chae, In-Whan Seong, Jung-Han Yoon, Suk-Kyu Oh, Doo-Il Kim, Keum-Soo Park, Seung-Woon Rha, Yang-Soo Jang, Jang-Ho Bae, Taeg-Jong Hong, Myeong-Chan Cho, Young-Jo Kim, Myung-Ho Jeong, Min-Jung Kim, Sue K. Park, In-Ho Chae, Hyo-Soo Kim. (2010) Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 3:5, 498-506
CrossRef69
Tullio Palmerini, Chiara Barozzi, Luciana Tomasi, Diego Sangiorgi, Antonio Marzocchi, Stefano De Servi, Paolo Ortolani, Letizia Bacchi Reggiani, Laura Alessi, Giulia Lauria, Mirna Bassi, Angelo Branzi. (2010) A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. Thrombosis Research 125:4, 309-314
CrossRef70
Gianluca Campo, Francesco Saia, Gianfranco Percoco, Antonio Manari, Andrea Santarelli, Luigi Vignali, Elisabetta Varani, Alberto Benassi, Pietro Sangiorgio, Fabio Tarantino, Paolo Magnavacchi, Rossana De Palma, Paolo Guastaroba, Antonio Marzocchi. (2010) Long-term outcome after drug eluting stenting in patients with ST-segment Elevation Myocardial Infarction. International Journal of Cardiology 140:2, 154-160
CrossRef71
S. Silber, M. Borggrefe, G. Hasenfuß, V. Falk, A. Kastrati, M. Weis, C.W. Hamm. (2010) Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI). Der Kardiologe 4:2, 84-92
CrossRef72
Asmir I. Syed, Itsik Ben-Dor, Yanlin Li, Sara D. Collins, Manuel A. Gonzalez, Michael A. Gaglia, Gabriel Maluenda, Cedric Delhaye, Kohei Wakabayashi, Laurant Bonello, Axel De Labriolle, Loic Belle, Rebecca Torguson, Zhenyi Xue, Kimberly Kaneshige, Nelson Bernardo, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2010) Outcomes in Diabetic Versus Nondiabetic Patients Who Present With Acute Myocardial Infarction and Are Treated With Drug-Eluting Stents. The American Journal of Cardiology 105:6, 819-825
CrossRef73
Scot Garg, Patrick Serruys. (2010) Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Review of Cardiovascular Therapy 8:3, 449-470
CrossRef74
Federico Piscione, Raffaele Piccolo, Salvatore Cassese, Gennaro Galasso, Roberta De Rosa, Claudia D’Andrea, Massimo Chiariello. (2010) Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention 5:7, 853-860
CrossRef75
Roberta Rossini, Giuseppe Musumeci, Alessandro Aprile, Orazio Valsecchi. (2010) Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. Expert Review of Pharmacoeconomics & Outcomes Research 10:1, 49-61
CrossRef76
Roberto Violini, Carmine Musto, Francesco De Felice, Marco Stefano Nazzaro, Alberta Cifarelli, Tommasangelo Petitti, Rosario Fiorilli. (2010) Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 55:8, 810-814
CrossRef77
Rahul Sakhuja, Laura Mauri. (2010) Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. Annual Review of Medicine 61:1, 215-231
CrossRef78
Pierre-Frédéric Keller, Marco Roffi. 2010. Acute Coronary Syndromes. , 1-22.
CrossRef79
Stéphane Cook. 2010. Modern Coronary Stenting. , 23-39.
CrossRef80
Sandhir B. Prasad, Walid Ahmar, Yuvaraj Malaiapan, Ian T. Meredith. (2010) Drug-eluting Stents for the Treatment of Acute Myocardial Infarction: The View to the HORIZONS. Heart, Lung and Circulation 19:1, 11-18
CrossRef81
Katsumi Inoue. (2010) Drug-Eluting Stents Are Not Indicated for Patients With Acute Coronary Syndrome. Circulation Journal 74:10, 2232-2238
CrossRef82
Yian-Ping Lee, Edgar Tay, Chi Hang Lee, Adrian Low, Swee Guan Teo, Kian Keong Poh, Wee-Tiong Yeo, Jimmy Lim, Ing Han Lim, Yean Teng Lim, Huay Cheem Tan. (2010) Endothelial progenitor cell capture stent implantation in patients with ST-segment elevation acute myocardial infarction: one year follow-up. EuroIntervention 5:6, 698-702
CrossRef83
Roy Beinart, Raed Abu Sham'a, Amit Segev, Hanoch Hod, Victor Guetta, Michael Shechter, Valentina Boyko, Shlomo Behar, Shlomi Matetzky. (2010) The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome. American Heart Journal 159:1, 118-124
CrossRef84
Kyung Woo Park, Si-Hyuck Kang, Woo-Young Chung, Hae-Young Lee, Jin-Shik Park, Hyun-Jae Kang, Young-Seok Cho, Tae-Jin Youn, Bon-Kwon Koo, In-Ho Chae, Dong-Ju Choi, Seokyung Hahn, Byung-Joo Park, Hyo-Soo Kim. (2010) `Real World' Comparison of Drug-Eluting Stents vs Bare Metal Stents in the Treatment of Unselected Patients With Acute ST-Segment Elevation Myocardial Infarction. Circulation Journal 74:6, 1111-1120
CrossRef85
Zhan Gao, Yuejin Yang, Bo Xu, Jilin Chen, Shubin Qiao, Jianjun Li, Yongjian Wu, Xuewen Qin, Jinqing Yuan, Runlin Gao. (2009) Three Year Follow-up of the Sirolimus-Eluting Stent and the Paclitaxel-eluting Stent in Daily Practice. Clinical Cardiology 32:12, E63-E67
CrossRef86
Edoardo Camenzind, William Wijns, Laura Mauri, Eric Boersma, Keyur Parikh, Volkhard Kurowski, Runlin Gao, Christoph Bode, John P. Greenwood, Anthony Gershlick, William O'Neill, Patrick W. Serruys, Brenda Jorissen, P. Gabriel Steg. (2009) Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. American Heart Journal 158:6, 902-909.e5
CrossRef87
Jael Atary, Sandrin Bergheanu, Bas van der Hoeven, Douwe Atsma, Marianne Bootsma, Frank van der Kley, Katja Zeppenfeld, J. Wouter Jukema, Martin Schalij. (2009) Impact of sirolimus-eluting stent implantation compared to bare-metal stent implantation for acute myocardial infarction on coronary plaque composition at nine months follow-up: a Virtual Histology intravascular ultrasound analysis. Results from the Leiden MISSION! intervention study. EuroIntervention 5:5, 565-572
CrossRef88
Marco Valgimigli, Flavio Airoldi, Marco Zimarino. (2009) Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?. Journal of Cardiovascular Medicine 10:Suppl 1, S17-S26
CrossRef89
Emilio Di Lorenzo, Rosario Sauro, Attilio Varricchio, Michele Capasso, Tonino Lanzillo, Fiore Manganelli, Ciro Mariello, Francesco Siano, Maria Rosaria Pagliuca, Giovanni Stanco, Giuseppe Rosato, Giuseppe De Luca. (2009) Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: Four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. American Heart Journal 158:4, e43-e50
CrossRef90
Khung Keong Yeo, Joost Daemen, Jason Rogers, Patrick Serruys. (2009) The use of drug-eluting stents in ST-elevation myocardial infarction. EuroIntervention 5:4, 494-500
CrossRef91
Robert A. Byrne, Nikolaus Sarafoff, Adnan Kastrati, Albert Schömig. (2009) Drug-Eluting Stents in Percutaneous Coronary Intervention. Drug Safety 32:9, 749-770
CrossRef92
Daiji Yoshikawa, Satoshi Isobe, Hisashi Umeda, Tomoko Kawai, Takeshi Shimizu, Kentaro Yamashita, Hideki Ishii, Toyoaki Murohara. (2009) Three-year prognosis of Japanese patients with ST-elevation myocardial infarction treated with sirolimus-eluting stents. Coronary Artery Disease 20:6, 422-427
CrossRef93
A. V. Finn, G. Nakazawa, F. Kolodgie, R. Virmani. (2009) Drug eluting or bare metal stent for acute myocardial infarction: an issue of safety?. European Heart Journal 30:15, 1828-1830
CrossRef94
Cheol Ung Choi, Seung-Woon Rha, Kang-Yin Chen, Zhe Jin, Yoshiyasu Minami, Seung Yong Shin, Jin Oh Na, Soon Yong Suh, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh. (2009) Mid-term angiographic benefit of sirolimus-eluting stents compared with paclitaxel-eluting stents in patients with acute myocardial infarction. Journal of Cardiology 54:1, 80-85
CrossRef95
Giuseppe Luca, Marco Valgimigli, Christian Spaulding, Maurizio Menichelli, Hans Peter Brunner-La Rocca, Bas L. Hoeven, Emilio Lorenzo, Luis-S. Diaz Llera, Vincenzo Pasceri, Undine Pittl, Gianfranco Percoco, Roberto Violini, Gregg W. Stone. (2009) Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Journal of Thrombosis and Thrombolysis 28:2, 200-210
CrossRef96
Angela Migliorini, Renato Valenti. 2009. Techniques. , 45-66.
CrossRef97
Nicolas W. Shammas, Gail A. Shammas, Alex Hahn, Michael Jerin, Eric J. Dippel, Matthew Winter. (2009) In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center. Cardiovascular Revascularization Medicine 10:3, 151-155
CrossRef98
MANABU OGITA, TOMOHIRO NAKAMURA, NAOKI FUJIWARA, KENICHI SAKAKURA, HIROSHI FUNAYAMA, YOSHITAKA SUGAWARA, NORIFUMI KUBO, JUNYA AKO, SHINICHI MOMOMURA. (2009) Long-Term Clinical Follow-up after Sirolimus-Eluting Stent versus Bare Metal Stent Implantation in Patients with Acute Coronary Syndrome. Journal of Interventional Cardiology 22:3, 216-221
CrossRef99
Henri Roukoz, Anthony A. Bavry, Michael L. Sarkees, Girish R. Mood, Dharam J. Kumbhani, Mark G. Rabbat, Deepak L. Bhatt. (2009) Comprehensive Meta-Analysis on Drug-Eluting Stents versus Bare-Metal Stents during Extended Follow-up. The American Journal of Medicine 122:6, 581.e1-581.e10
CrossRef100
Yoseph Rozenman, Valentin Witzling, Israel Tamari, Vladimir Turkisher, Michael Kriviski, Christoph Bode, Patrick Henry, Emmanuel Teiger, Ana Cebrian, Hans-Peter Stoll, Christian Spaulding. (2009) Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON). EuroIntervention 5:2, 219-223
CrossRef101
Emilio Di Lorenzo, Giuseppe De Luca, Rosario Sauro, Attilio Varricchio, Michele Capasso, Tonino Lanzillo, Fiore Manganelli, Ciro Mariello, Francesco Siano, Maria Rosaria Pagliuca, Giovanni Stanco, Giuseppe Rosato. (2009) The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC: Cardiovascular Interventions 2:6, 515-523
CrossRef102
Meinrad Gawaz, Tobias Geisler. (2009) Coronary artery disease: Platelet activity: an obstacle for successful PCI. Nature Reviews Cardiology 6:6, 391-392
CrossRef103
Jochen Wöhrle, Thorsten Nusser, Simone Langenwalder, Vinzenz Heombach, Matthias Kochs. (2009) Carbon-coated Stents in Patients with Acute Coronary Syndromes. Clinical Cardiology 32:6, E1-E6
CrossRef104
Neville Kukreja, Yoshinobu Onuma, Patrick W Serruys. (2009) Xience V™ everolimus-eluting coronary stent. Expert Review of Medical Devices 6:3, 219-229
CrossRef105
Somjot S. Brar, Martin B. Leon, Gregg W. Stone, Roxana Mehran, Jeffrey W. Moses, Simerjeet K. Brar, George Dangas. (2009) Use of Drug-Eluting Stents in Acute Myocardial Infarction. Journal of the American College of Cardiology 53:18, 1677-1689
CrossRef106
Nieves Gonzalo, Peter Barlis, Patrick W. Serruys, Hector M. Garcia-Garcia, Yoshinobu Onuma, Jurgen Ligthart, Evelyn Regar. (2009) Incomplete Stent Apposition and Delayed Tissue Coverage Are More Frequent in Drug-Eluting Stents Implanted During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Than in Drug-Eluting Stents Implanted for Stable/Unstable Angina. JACC: Cardiovascular Interventions 2:5, 445-452
CrossRef107
Giuseppe De Luca, Harry Suryapranata, Gregg W. Stone, Paolo Marino. (2009) Reply to “Stenting versus plain old angioplasty in patients with ST segment elevation myocardial infarction: Understanding of the randomized trials”. International Journal of Cardiology 133:3, 396
CrossRef108
Raisuke Iijima, Robert A. Byrne, Alban Dibra, Gjin Ndrepepa, Christian Spaulding, Gerrit J. Laarman, Maurizio Menichelli, Marco Valgimigli, Emilio Di Lorenzo, Christoph Kaiser, Ilkka Tierala, Julinda Mehilli, Maarten J. Suttorp, Roberto Violini, Albert Schömig, Adnan Kastrati. (2009) Stents liberadores de fármacos frente a stents convencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados. Revista Española de Cardiología 62:4, 354-364
CrossRef109
Turgay Celik, Atila Iyisoy, Ejder Kardesoglu, Ersoy Isik. (2009) Stenting versus plain old angioplasty in patients with ST segment elevation myocardial infarction: Understanding of the randomized trials. International Journal of Cardiology 133:3, 394-396
CrossRef110
Mehmood Butt, Derek Connolly, Gregory YH Lip. (2009) Drug-eluting stents: a comprehensive appraisal. Future Cardiology 5:2, 141-157
CrossRef111
(2009) Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Revista Española de Cardiología 62:3, 293.e1-293.e47
CrossRef112
Gilles Montalescot, Stephen D Wiviott, Eugene Braunwald, Sabina A Murphy, C Michael Gibson, Carolyn H McCabe, Elliott M Antman. (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. The Lancet 373:9665, 723-731
CrossRef113
Cheol Ung Choi, Seung-Woon Rha, Kang-Yin Chen, Yong-Jian Li, Kanhaiya L. Poddar, Zhe Jin, Yoshiyasu Minami, Soon Yong Suh, Jin Oh Na, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh. (2009) Lack of Clinical Benefit of Improved Angiographic Results With Sirolimus-Eluting Stents Compared With Paclitaxel and Zotarolimus-Eluting Stents in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Circulation Journal 73:12, 2229-2235
CrossRef114
Federico Piscione, Raffaele Piccolo, Salvatore Cassese, Gennaro Galasso, Massimo Chiariello. (2009) Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef115
Michael S. Lee, Dario Sillano, Azeem Latib, Alaide Chieffo, Giuseppe Biondi Zoccai, Ravi Bhatia, Imad Sheiban, Antonio Colombo, Jonathan Tobis. (2009) Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction. Catheterization and Cardiovascular Interventions 73:1, 15-21
CrossRef116
Manesh R. Patel, Matthias E. Pfisterer, Amadeo Betriu, Petr Widmisky, David R. Holmes, William W. O'Neill, Amanda Stebbins, Frans Van de Werf, Paul W. Armstrong, Christopher B. Granger. (2009) Comparison of Six-Month Outcomes for Primary Percutaneous Revascularization for Acute Myocardial Infarction With Drug-Eluting Versus Bare Metal Stents (from the APEX-AMI Study). The American Journal of Cardiology 103:2, 181-186
CrossRef117
Smiljana V. Pavlovic, Dragana P. Sobic-Saranovic, Branko D. Beleslin, Miodrag C. Ostojic, Milan A. Nedeljkovic, Vojislav L. Giga, Zorica R. Petrasinovic, Vera M. Artiko, Mila V. Todorovic-Tirnanic, Vladimir B. Obradovic. (2009) One-year follow-up of myocardial perfusion and function evaluated by gated SPECT MIBI in patients with earlier myocardial infarction and chronic total occlusion. Nuclear Medicine Communications 30:1, 68-75
CrossRef118
Kazuaki Nishio, Meiei Shigemitsu, Yusuke Kodama, Noburu Konno, Takashi Katagiri, Youichi Kobayashi. (2009) Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus. Cardiovascular Revascularization Medicine 10:1, 5-11
CrossRef119
Jozef Jakabc
in, Radim S
CrossRef120
Giuseppe Tarantini, Angelo Ramondo, Massimo Napodano, Enrico Favaretto, Arianna Gardin, Claudio Bilato, Georghios Nesseris, Vincenzo Tarzia, Filippo Cademartiri, Gino Gerosa, Sabino Iliceto. (2009) PCI versus CABG for multivessel coronary disease in diabetics. Catheterization and Cardiovascular Interventions 73:1, 50-58
CrossRef121
Yasmin S. Hamirani, Ismaila Jibrin, Daniel Abraham, Barry Merriman, Charlene Wenz, Raymond D. Bahr. (2008) Paclitaxel-Eluting Versus Bare-Metal Stents in Acute ST Elevation Myocardial Infarction (STEMI). Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 7:4, 232-238
CrossRef122
Bruce R. Brodie, Thomas Stuckey, William Downey, Angela Humphrey, Marcy Nussbaum, Sherry Laurent, Barbara Bradshaw, Chris Metzger, James Hermiller, Fred Krainin, Stanley Juk, Barry Cheek, Peter Duffy, Charles A. Simonton, . (2008) Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: Results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Catheterization and Cardiovascular Interventions 72:7, 893-900
CrossRef123
CINDY L. GRINES, TERESA R. NELSON, ROBERT D. SAFIAN, GEORGE HANZEL, JAMES A. GOLDSTEIN, SIMON DIXON. (2008) A Bayesian Meta-Analysis Comparing AngioJet ® Thrombectomy to Percutaneous Coronary Intervention Alone in Acute Myocardial Infarction. Journal of Interventional Cardiology 21:6, 459-482
CrossRef124
Young-Hoon Jeong, Seung-Whan Lee, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, Duk-Woo Park, Young-Hak Kim. (2008) Biomarkers on Admission for the Prediction of Cardiovascular Events After Primary Stenting in Patients with ST-Elevation Myocardial Infarction. Clinical Cardiology 31:12, 572-579
CrossRef125
Nadia Garro, Davide Capodanno, Valeria Cammalleri, Corrado Tamburino. (2008) Very late thrombosis in acute myocardial infarction: drug-eluting versus uncoated stents. EuroIntervention 4:3, 324-330
CrossRef126
, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P. G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , S. Silber, F. V. Aguirre, N. Al-Attar, E. Alegria, F. Andreotti, W. Benzer, O. Breithardt, N. Danchin, C. D. Mario, D. Dudek, D. Gulba, S. Halvorsen, P. Kaufmann, R. Kornowski, G. Y. H. Lip, F. Rutten. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. European Heart Journal 29:23, 2909-2945
CrossRef127
Jae-Youn Moon, Jong Won Chung, Ju Han Kim, Young Keun Ahn, Myung Ho Jeong. (2008) Simultaneous subacute stent thrombosis of two sirolimus-eluting stents in a patient treated by ReoPro, thrombus aspiration and triple anti-platelet agents. International Journal of Cardiology 130:1, e25-e29
CrossRef128
Jozef Jakabčin, Marian Bystroň, Radim Špaček, Josef Veselka, Martin Kvašňak, Petr Kala, Jaroslav Malý, Pavel Červinka. (2008) The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. Journal of Thrombosis and Thrombolysis 26:2, 154-158
CrossRef129
Mauri, Laura, Silbaugh, Treacy S., Garg, Pallav, Wolf, Robert E., Zelevinsky, Katya, Lovett, Ann, Varma, Manu R., Zhou, Zheng, Normand, Sharon-Lise T., . (2008) Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction. New England Journal of Medicine 359:13, 1330-1342
Full Text130
Ph. G. Steg, K. A.A. Fox, K. A. Eagle, M. Furman, F. Van de Werf, G. Montalescot, S. G. Goodman, A. Avezum, W. Huang, J. M. Gore, . (2008) Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. European Heart Journal 30:3, 321-329
CrossRef131
John P Girod, Suresh R Mulukutla, Oscar C Marroquin. (2008) Off-label use of stents: bare-metal versus drug-eluting stents. Expert Review of Cardiovascular Therapy 6:8, 1095-1106
CrossRef132
Rosetta Melfi, Annunziata Nusca, Giuseppe Patti, Germano Sciascio. (2008) The risks and benefits of drug-eluting stents in the setting of STEMI. Current Cardiology Reports 10:5, 402-406
CrossRef133
Stephan Windecker, Patrick W Serruys, Simon Wandel, Pawel Buszman, Stanislaw Trznadel, Axel Linke, Karsten Lenk, Thomas Ischinger, Volker Klauss, Franz Eberli, Roberto Corti, William Wijns, Marie-Claude Morice, Carlo di Mario, Simon Davies, Robert-Jan van Geuns, Pedro Eerdmans, Gerrit-Anne van Es, Bernhard Meier, Peter Jüni. (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. The Lancet 372:9644, 1163-1173
CrossRef134
Marco Valgimigli, Nicole Mittmann, David J. Cohen, Gianluca Campo, Pierre K. Isogai, Soo Jin Seung, Brian Dulisse, Chiara Arcozzi, Paolo Squasi, Gianfranco Percoco, Roberto Ferrari. (2008) A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. International Journal of Cardiology 128:1, 53-61
CrossRef135
Pasi Karjalainen, Antti Ylitalo, Matti Niemelä, Kari Kervinen, Timo Mäkikallio, Mikko Pietilä, Jussi Sia, Petri Tuomainen, Kai Nyman, K.E. Airaksinen. (2008) Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention 4:2, 234-241
CrossRef136
Rik Hermanides, Jan Paul Ottervanger. (2008) Treatment of ST-elevation myocardial infarction. Future Cardiology 4:4, 391-397
CrossRef137
David P. Faxon. (2008) New data on early management of patients with ST-elevation myocardial infarction. Current Cardiology Reports 10:4, 291-298
CrossRef138
Roxana Mehran, Bruce Brodie, David A. Cox, Cindy L. Grines, Barry Rutherford, Deepak L. Bhatt, George Dangas, Fred Feit, E. Magnus Ohman, Helen Parise, Martin Fahy, Alexandra J. Lansky, Gregg W. Stone. (2008) The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal 156:1, 44-56
CrossRef139
Ran Kornowski. (2008) Drug-eluting stents in ST elevation myocardial infarction: In light of the PROSIT trial. Catheterization and Cardiovascular Interventions 72:1, 33-35
CrossRef140
Mehdi H. Shishehbor, Reza Amini, Leonardo P.J. Oliveria, Inder M. Singh, Peter Kelly, Deepak L. Bhatt, Samir R. Kapadia, Stephen G. Ellis, Patrick L. Whitlow, Sorin J. Brener. (2008) Comparison of Drug-Eluting Stents Versus Bare-Metal Stents for Treating ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 1:3, 227-232
CrossRef141
George W. Vetrovec. (2008) Drug eluting stents in AMI: Keep the data coming. Catheterization and Cardiovascular Interventions 71:6, 770-771
CrossRef142
Pieter J. Vlaar, Charanjit S. Rihal, Mandeep Singh, Ryan Lennon, Henry H. Ting, John F. Bresnahan, David R. Holmes. (2008) Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort. Catheterization and Cardiovascular Interventions 71:6, 764-769
CrossRef143
Maurits Dirksen, Maarten Vink, Maarten Suttorp, Jan Tijssen, Mark Patterson, Ton Slagboom, Ferdinand Kiemeneij, Gerrit Laarman. (2008) Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. EuroIntervention 4:1, 64-70
CrossRef144
Chong-Hiok Tan, Myeong-Ki Hong, Cheol-Whan Lee, Young-Hak Kim, Chang-Hoon Lee, Seong-Wook Park, Seung-Jung Park. (2008) Percutaneous coronary intervention with stenting of left main coronary artery with drug-eluting stent in the setting of acute ST elevation myocardial infarction. International Journal of Cardiology 126:2, 224-228
CrossRef145
Giuseppe De Luca, Harry Suryapranata, Gregg W. Stone, David Antoniucci, Giuseppe Biondi-Zoccai, Adnan Kastrati, Massimo Chiariello, Paolo Marino. (2008) Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. International Journal of Cardiology 126:1, 37-44
CrossRef146
Edward L. Hannan, Michael Racz, Gary Walford, David R. Holmes, Robert H. Jones, Samin Sharma, Stanley Katz, Spencer B. King. (2008) Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 1:2, 129-135
CrossRef147
Stephen D Wiviott, Eugene Braunwald, Carolyn H McCabe, Ivan Horvath, Matyas Keltai, Jean-Paul R Herrman, Frans Van de Werf, William E Downey, Benjamin M Scirica, Sabina A Murphy, Elliott M Antman. (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. The Lancet 371:9621, 1353-1363
CrossRef148
Ana M. Planas-del Viejo, Francisco Pomar-Domingo, Juan V. Vilar-Herrero, Victoria Jacas-Osborn, Mercedes Nadal-Barangé, Emilio Pérez-Fernández. (2008) Resultados clínicos y angiográficos tardíos de stents liberadores de fármacos en pacientes con infarto agudo de miocardio con elevación del ST. Revista Española de Cardiología 61:4, 360-368
CrossRef149
Henning Kelbæk, Christian J. Terkelsen, Steffen Helqvist, Jens F. Lassen, Peter Clemmensen, Lene Kløvgaard, Anne Kaltoft, Thomas Engstrøm, Hans E. Bøtker, Kari Saunamäki, Lars R. Krusell, Erik Jørgensen, Hans-Henrik T. Hansen, Evald H. Christiansen, Jan Ravkilde, Lars Køber, Klaus F. Kofoed, Leif Thuesen. (2008) Randomized Comparison of Distal Protection Versus Conventional Treatment in Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:9, 899-905
CrossRef150
José M. de la Torre-Hernández, Fernando Alfonso, Felipe Hernández, Jaime Elizaga, Marcelo Sanmartin, Eduardo Pinar, Iñigo Lozano, Jose M. Vazquez, Javier Botas, Armando Perez de Prado, Jose M. Hernández, Juan Sanchis, Juan M. Ruiz Nodar, Alfredo Gomez-Jaume, Mariano Larman, Jose A. Diarte, Javier Rodríguez-Collado, Jose R. Rumoroso, Jose R. Lopez-Minguez, Josepa Mauri. (2008) Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology 51:10, 986-990
CrossRef151
Nestor Mercado, Simon R. Dixon, William W. O'Neill. 2008. Primary Percutaneous Coronary Intervention. , 91-117.
CrossRef152
David M Briscoe, Soumitro Pal. (2008) Assessing the vascular effects of early erythropoietin use in pediatric renal transplant recipients. Nature Clinical Practice Nephrology 4:3, 136-137
CrossRef153
Giuseppe De Luca, Harry Suryapranata, Paolo Marino. (2008) Reperfusion Strategies in Acute ST-Elevation Myocardial Infarction: An Overview of Current Status. Progress in Cardiovascular Diseases 50:5, 352-382
CrossRef154
Bas L. van der Hoeven, Su-San Liem, J. Wouter Jukema, Navin Suraphakdee, Hein Putter, Jouke Dijkstra, Douwe E. Atsma, Marianne Bootsma, Katja Zeppenfeld, Pranobe V. Oemrawsingh, Ernst E. van der Wall, Martin J. Schalij. (2008) Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction: 9-Month Angiographic and Intravascular Ultrasound Results and 12-Month Clinical Outcome. Journal of the American College of Cardiology 51:6, 618-626
CrossRef155
Frank D. Weber, Henrik Schneider, Marcus Wiemer, Thomas Pfannebecker, Ulrich Tebbe, Christian W. Hamm, Jochen Senges, Steffen Schneider, Christoph A. Nienaber. (2008) Sirolimus eluting stent (Cypher™) in patients with diabetes mellitus: results from the German Cypher Stent Registry. Clinical Research in Cardiology 97:2, 105-109
CrossRef156
Henry H. Ting, Matthew T. Roe, Bernard J. Gersh, John A. Spertus, John S. Rumsfeld, Fang-Shu Ou, John Kao, Kirsten Hall Long, David R. Holmes, Eric D. Peterson. (2008) Factors Associated With Off-Label Use of Drug-Eluting Stents in Patients With ST-Elevation Myocardial Infarction. The American Journal of Cardiology 101:3, 286-292
CrossRef157
Kazumiki Nomoto, Ikuyoshi Watanabe, Tomiya Oba, Ken Nagao, Toshio Kushiro, Atsushi Hirayama. (2008) Safety and Efficacy of Sirolimus-Eluting Stent in Patients With Acute Coronary Syndrome Undergoing Emergency Procedure. Circulation Journal 72:7, 1054-1058
CrossRef158
R. Kornowski, H. Vaknin-Assa, E. Lev, I. Ben-Dor, I. Teplitsky, E. Rechavia, D. Brosh, S. Fuchs, A. Assali. (2008) Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction. Acute Cardiac Care 10:3, 167-172
CrossRef159
Steve Ramcharitar, Matthias Hochadel, Anne Gaster, Yoshinobu Onuma, Anselm Gitt, Patrick Serruys. (2008) An insight into the current use of drug eluting stents in acute and elective percutaneous coronary interventions in Europe. A report on the EuroPCI Survey. EuroIntervention 3:4, 429-441
CrossRef160
(2008) 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 71:1, E1-E40
CrossRef161
Jae-Hwan Lee, Hyun-Sook Kim, Seung-Whan Lee, Jae-Hyeong Park, Si-Wan Choi, Jin-Ok Jeong, Yoonhaeng Cho, Naehee Lee, Kyoung-Suk Rhee, Jae-Ki Ko, In-Whan Seong. (2008) Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions
CrossRef162
William S. Weintraub, Deborah Ehrenthal. (2008) Establishing the effectiveness of coronary intervention for acute myocardial infarction. American Heart Journal 155:1, 6-8
CrossRef163
Spencer B. King, Sidney C. Smith, John W. Hirshfeld, Alice K. Jacobs, Douglass A. Morrison, David O. Williams. (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:2, 172-209
CrossRef164
Tina L. Pinto Slottow, Daniel H. Steinberg, Probal Roy, Aamir Javaid, Ashesh N. Buch, Teruo Okabe, Zhenyi Xue, Kimberly Smith, Rebecca Torguson, Augusto D. Pichard, Lowell F. Satler, William O. Suddath, Kenneth M. Kent, Ron Waksman. (2008) Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovascular Revascularization Medicine 9:1, 24-28
CrossRef165
Sang Rok Lee, Myung Ho Jeong, Young Keun Ahn, Shung Chull Chae, Seung Ho Hur, Young Jo Kim, In Whan Seong, Jei Keon Chae, Taek Jong Hong, Jae Young Rhew, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jin Kim, Yang Soo Jang, Seung Jung Park, Korea Acute Myocardial Infarction R. (2008) Clinical Safety of Drug-Eluting Stents in the Korea Acute Myocardial Infarction Registry. Circulation Journal 72:3, 392-398
CrossRef166
William E. Braun. 2008. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 1009-1033.
CrossRef167
Tomoko Ohtsuka Machino, Masahiro Toyama, Kenichi Obara, Noriyuki Takeyasu, Shigeyuki Watanabe, Kazutaka Aonuma. (2008) Effect of Hospital Case Volume on Treatment and In-Hospital Outcomes in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction. International Heart Journal 49:3, 249-260
CrossRef168
Ajay J. Kirtane, Martin B. Leon. (2007) Clinical Use of Sirolimus-Eluting Stents. Cardiovascular Drug Reviews 25:4, 316-332
CrossRef169
JEFFREY J. POPMA, BONNIE WEINER, MICHAEL J. COWLEY, CHARLES SIMONTON, DAN McCORMICK, TED FELDMAN. (2007) FDA Advisory Panel on the Safety and Efficacy of Drug-Eluting Stents: Summary of Findings and Recommendations. Journal of Interventional Cardiology 20:6, 425-446
CrossRef170
Michael Kindermann, Oliver Adam, Nikos Werner, Michael Böhm. (2007) Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007. Clinical Research in Cardiology 96:11, 767-786
CrossRef171
Raúl Moreno, Christian Spaulding, Gert Jan Laarman, Ilkka Tierala, Christoph Kaiser, Jose-Luis Lopez-Sendon. (2007) Effectiveness and safety of paclitaxel-eluting stents in patients with ST-segment elevation acute myocardial infarction. EuroIntervention 3:3, 386-391
CrossRef172
Pavel Červinka, Jozef Jakabčin, Jiři Jäger, Josef Veselka, Petr Kala, Jaroslav Maly. (2007) Long-term health outcome and mortality evaluation after invasive coronary treatment using drug-eluting stents: HOME DES registry. Coronary Artery Disease 18:7, 577-581
CrossRef173
Gregg W. Stone, Simon R. Dixon, Cindy L. Grines, David A. Cox, John G. Webb, Bruce R. Brodie, John J. Griffin, Jack L. Martin, Martin Fahy, Roxana Mehran, Todd D. Miller, Raymond J. Gibbons, William W. O’Neill. (2007) Predictors of Infarct Size After Primary Coronary Angioplasty in Acute Myocardial Infarction from Pooled Analysis from Four Contemporary Trials. The American Journal of Cardiology 100:9, 1370-1375
CrossRef174
Steffen Helqvist, Henning Kelbæk, Leif Thuesen, Lene Kløvgaard, Lars Krusell, Erik Jørgensen, Hans Bøtker, Gunnar Jensen, Jens Lassen, Per Thayssen, Anders Galløe, Kari Saunamäki. (2007) Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. EuroIntervention 3:3, 309-314
CrossRef175
J. Dawn Abbott, Matthew R. Voss, Mamoo Nakamura, Howard A. Cohen, Faith Selzer, Kevin E. Kip, Helen A. Vlachos, Robert L. Wilensky, David O. Williams. (2007) Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical Practice. Journal of the American College of Cardiology 50:21, 2029-2036
CrossRef176
Jason Ryan, Donald E. Cutlip, David J. Cohen, Duane S. Pinto. (2007) Drug eluting stents for ST-elevation myocardial infarction: risk and benefit. Journal of Thrombosis and Thrombolysis 24:3, 293-299
CrossRef177
Tu, Jack V., Bowen, James, Chiu, Maria, Ko, Dennis T., Austin, Peter C., He, Yaohua, Hopkins, Robert, Tarride, Jean-Eric, Blackhouse, Gord, Lazzam, Charles, Cohen, Eric A., Goeree, Ron, . (2007) Effectiveness and Safety of Drug-Eluting Stents in Ontario. New England Journal of Medicine 357:14, 1393-1402
Full Text178
Santiago Jimenez-Valero, Belen Santos, Fernando Pajin, Tomas Canton, Esther Lazaro, Jose Moreu, Gonzalo Hernandez, Luis Rodriguez Padial. (2007) Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction. Catheterization and Cardiovascular Interventions 70:4, 492-497
CrossRef179
Mitsutoshi Oguri, Kimihiko Kato, Takeshi Hibino, Kiyoshi Yokoi, Tomonori Segawa, Hitoshi Matsuo, Sachiro Watanabe, Yoshinori Nozawa, Toyoaki Murohara, Yoshiji Yamada. (2007) Genetic risk for restenosis after coronary stenting. Atherosclerosis 194:2, e172-e178
CrossRef180
Victor L. Serebruany. (2007) The “Clopidogrel Resistance” Trap. The American Journal of Cardiology 100:6, 1044-1046
CrossRef181
S. Manzo-Silberman, O. Varenne, C. Spaulding. (2007) Limites des stents actifs. Annales de Cardiologie et d'Angéiologie 56, S48-S52
CrossRef182
Moshe Rav-Acha, Leeor Plot, Nathan Peled, Howard Amital. (2007) Coronary involvement in Takayasu's arteritis. Autoimmunity Reviews 6:8, 566-571
CrossRef183
Rahul Bose, Gaurav Gupta, Paul A. Grayburn, Emily A. Laible, Mi Jung Kang, James W. Choi. (2007) Safety of Drug-Eluting Stents in the Coronary Artery in ST-Elevation Myocardial Infarction at a Single High-Volume Medical Center. The American Journal of Cardiology 100:6, 949-952
CrossRef184
Christoph Stettler, Simon Wandel, Sabin Allemann, Adnan Kastrati, Marie Claude Morice, Albert Schömig, Matthias E Pfisterer, Gregg W Stone, Martin B Leon, José Suarez de Lezo, Jean-Jacques Goy, Seung-Jung Park, Manel Sabaté, Maarten J Suttorp, Henning Kelbaek, Christian Spaulding, Maurizio Menichelli, Paul Vermeersch, Maurits T Dirksen, Pavel Cervinka, Anna Sonia Petronio, Alain J Nordmann, Peter Diem, Bernhard Meier, Marcel Zwahlen, Stephan Reichenbach, Sven Trelle, Stephan Windecker, Peter Jüni. (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. The Lancet 370:9591, 937-948
CrossRef185
Cheol Whan Lee, Chong-Hiok Tan, Jon Suh, Se-Whan Lee, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Myeong-Ki Hong, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park. (2007) Sirolimus-eluting stent implantation for treatment of proximal left anterior descending coronary artery lesions: Long-term outcome and predictors of adverse cardiac events. Catheterization and Cardiovascular Interventions 70:3, 368-373
CrossRef186
S.K. Gupta, Amit Malik. (2007) Primary Percutaneous Coronary Intervention. Apollo Medicine 4:3, 197-201
CrossRef187
TANIA CHECHI, GUIDO VITTORI, GIUSEPPE G.L. BIONDI ZOCCAI, SABINE VECCHIO, ELENA FALCHETTI, GAIA SPAZIANI, GIORGIO BALDERESCHI, CRISTINA GIGLIOLI, SERAFINA VALENTE, MASSIMO MARGHERI. (2007) Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION). Journal of Interventional Cardiology 20:4, 282-291
CrossRef188
S. Silber, M. Borggrefe, M. Böhm, H.M. Hoffmeister, R. Dietz, G. Ertl, G. Heusch. (2007) Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). Der Kardiologe 1:2, 84-111
CrossRef189
Enrico Mangieri, Gaetano Tanzilli, Cesare Greco, Francesco Pelliccia, Paolo Puddu, Maria Acconcia, Vincenzo Paravati, Carlo Gaudio. (2007) Clinical results of two year dual antiplatelet therapy after primary percutaneous coronary intervention with paclitaxel-eluting stents: a single centre study. EuroIntervention 3:2, 222-227
CrossRef190
Georgios Sianos, Michail I. Papafaklis, Joost Daemen, Sofia Vaina, Carlos A. van Mieghem, Ron T. van Domburg, Lampros K. Michalis, Patrick W. Serruys. (2007) Angiographic Stent Thrombosis After Routine Use of Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, 573-583
CrossRef191
Ralf Zahn, C. W. Hamm, S. Schneider, U. Zeymer, G. Richardt, M. Kelm, B. Levenson, T. Bonzel, U. Tebbe, G. Sabin, C. A. Nienaber, Thomas Pfannebecker, J. Senges, . (2007) The Sirolimus-eluting coronary stent in daily routine practice in Germany:. Clinical Research in Cardiology 96:8, 548-556
CrossRef192
Sanjay Kaul, Prediman K. Shah, George A. Diamond. (2007) As Time Goes By. Journal of the American College of Cardiology 50:2, 128-137
CrossRef193
Lisette Okkels Jensen, Michael Maeng, Anne Kaltoft, Per Thayssen, Hans Henrik Tilsted Hansen, Morten Bottcher, Jens Flensted Lassen, Lars Romer Krussel, Klaus Rasmussen, Knud Noerregaard Hansen, Lars Pedersen, Soeren Paaske Johnsen, Henrik Toft Soerensen, Leif Thuesen. (2007) Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. Journal of the American College of Cardiology 50:5, 463-470
CrossRef194
Ronen Jaffe, Bradley H. Strauss. (2007) Late and Very Late Thrombosis of Drug-Eluting Stents. Journal of the American College of Cardiology 50:2, 119-127
CrossRef195
Richard J. Gumina. (2007) New Trials and Therapies for Acute Myocardial Infarction. Medical Clinics of North America 91:4, 729-749
CrossRef196
David R. Holmes, Dean J. Kereiakes, Warren K. Laskey, Antonio Colombo, Stephen G. Ellis, Timothy D. Henry, Jeffrey J. Popma, Patrick W.J.C. Serruys, Takeshi Kimura, David O. Williams, Stephan Windecker, Mitchell W. Krucoff. (2007) Thrombosis and Drug-Eluting Stents. Journal of the American College of Cardiology 50:2, 109-118
CrossRef197
Marco Valgimigli, Gianluca Campo, Chiara Arcozzi, Patrizia Malagutti, Roberto Carletti, Fabrizio Ferrari, Dario Barbieri, Giovanni Parrinello, Gianfranco Percoco, Roberto Ferrari. (2007) Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction. Journal of the American College of Cardiology 50:2, 138-145
CrossRef198
W. J. van Gaal, D. Clark, P. Barlis, C. C. S. Lim, J. Johns, M. Horrigan. (2007) Results of primary percutaneous coronary intervention in a consecutive group of patients with acute ST elevation myocardial infarction at a tertiary Australian centre. Internal Medicine Journal 37:7, 464-471
CrossRef199
Luis-S Díaz de la Llera, Sara Ballesteros, Jaime Nevado, Mónica Fernández, Manuel Villa, Ángel Sánchez, Gabriel Retegui, Dolores García, Ángel Martínez. (2007) Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. American Heart Journal 154:1, 164.e1-164.e6
CrossRef200
Simon R. Dixon, Cindy L. Grines, William W. O’Neill. (2007) The Year in Interventional Cardiology. Journal of the American College of Cardiology 50:3, 270-285
CrossRef201
L. Iri Kupferwasser, Allen M. Amorn, Nikhil Kapoor, Michael S. Lee, Saibal Kar, Bojan Cercek, Suhail Dohad, James Mirocha, James S. Forrester, Prediman K. Shah, Raj R. Makkar. (2007) Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction. Catheterization and Cardiovascular Interventions 70:1, 1-8
CrossRef202
Marco Valgimigli, Leonardo Bolognese, Maurizio Anselmi, Gianluca Campo, Alfredo E. Rodriguez, Nicoletta de Cesare, David J. Cohen, Imad Sheiban, Salvatore Colangelo, Giampaolo Pasquetto, Martial Hamon, Pascal Vranckx, Maurizio Ferrario, Francesco Prati, Pierfrancesco Agostoni, Patrizia Malagutti, Chiara Arcozzi, Giovanni Parrinello, Corrado Vassanelli, Roberto Ferrari, Gianfranco Percoco. (2007) Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction. American Heart Journal 154:1, 39-45
CrossRef203
Leslie Levin, Ron Goeree, Nancy Sikich, Birthe Jorgensen, Melissa C. Brouwers, Tony Easty, Catherine Zahn. (2007) Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: The Ontario experience. International Journal of Technology Assessment in Health Care 23:03,
CrossRef204
Adnan Kastrati, Albert Schömig. (2007) Drug-Eluting Stents. Journal of the American College of Cardiology 50:2, 146-148
CrossRef205
J. Dawn Abbott, David O. Williams. (2007) Lessons Learned in the Drug-Eluting Stent Era. The American Heart Hospital Journal 5:3, 169-172
CrossRef206
Morton J. Kern. (2007) Drug-Eluting Stents: The Continuing Controversy?A Perspective on the Downside of Drug-Eluting Stents. The American Heart Hospital Journal 5:3, 159-164
CrossRef207
Mark G. Rabbat, Anthony A. Bavry, Deepak L. Bhatt. (2007) Drug-Eluting Stents: Can We Move Beyond Stent Thrombosis?. The American Heart Hospital Journal 5:3, 155-158
CrossRef208
Aloke V. Finn, Gaku Nakazawa, Frank D. Kolodgie, Renu Virmani. (2007) Controversies Surrounding the Use of Drug-Eluting Stents. The American Heart Hospital Journal 5:3, 141-145
CrossRef209
Olaf Schouten, Jeroen J Bax, Don Poldermans. (2007) Management of patients with cardiac stents undergoing noncardiac surgery. Current Opinion in Anaesthesiology 20:3, 274-278
CrossRef210
H. Vernon Anderson, Richard W. Smalling, Timothy D. Henry. (2007) Drug-Eluting Stents for Acute Myocardial Infarction
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 49:19, 1931-1933
CrossRef211
Prospero B. Gogo, Harold L. Dauerman, Jyotsna Mulgund, E. Magnus Ohman, Manesh R. Patel, David J. Cohen, Jorge F. Saucedo, Robert A. Harrington, W. Brian Gibler, Sidney C. Smith, Eric D. Peterson, Matthew T. Roe. (2007) Changes in Patterns of Coronary Revascularization Strategies for Patients With Acute Coronary Syndromes (from the CRUSADE Quality Improvement Initiative). The American Journal of Cardiology 99:9, 1222-1226
CrossRef212
Vincenzo Pasceri, Giuseppe Patti, Giulio Speciale, Christian Pristipino, Giuseppe Richichi, Germano Di Sciascio. (2007) Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. American Heart Journal 153:5, 749-754
CrossRef213
H. J. M. G. Nelissen-Vrancken. (2007) Effectiviteit van geneesmiddelgecoate stents bij acuut myocardinfarct. Medisch-Farmaceutische Mededelingen 45:5, 149-150
CrossRef214
Maurizio Menichelli, Antonio Parma, Edoardo Pucci, Rosario Fiorilli, Francesco De Felice, Marco Nazzaro, Alessia Giulivi, Domenico Alborino, Arianna Azzellino, Roberto Violini. (2007) Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). Journal of the American College of Cardiology 49:19, 1924-1930
CrossRef215
Joost Daemen, Shuzou Tanimoto, Héctor M. García-García, Neville Kukreja, Meike van de Sande, Georgios Sianos, Peter P.T. de Jaegere, Ron T. van Domburg, Patrick W. Serruys. (2007) Comparison of Three-Year Clinical Outcome of Sirolimus- and Paclitaxel-Eluting Stents Versus Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction (from the RESEARCH and T-SEARCH Registries). The American Journal of Cardiology 99:8, 1027-1032
CrossRef216
Alexandre Abizaid. (2007) Sirolimus-eluting coronary stents: a review. Vascular Health and Risk Management 3:2, 191-201
CrossRef217
Kastrati, Adnan, Mehilli, Julinda, Pache, Jürgen, Kaiser, Christoph, Valgimigli, Marco, Kelbæk, Henning, Menichelli, Maurizio, Sabaté, Manel, Suttorp, Maarten J., Baumgart, Dietrich, Seyfarth, Melchior, Pfisterer, Matthias E., Schömig, Albert, . (2007) Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine 356:10, 1030-1039
Full Text218
Victor Legrand. (2007) Therapy Insight: diabetes and drug-eluting stents. Nature Clinical Practice Cardiovascular Medicine 4:3, 143-150
CrossRef219
Robert J. Applegate, Matthew T. Sacrinty, Michael A. Kutcher, Talal T. Baki, Sanjay K. Gandhi, Renato M. Santos, William C. Little. (2007) Comparison of Drug-Eluting Versus Bare Metal Stents on Later Frequency of Acute Myocardial Infarction and Death. The American Journal of Cardiology 99:3, 333-338
CrossRef220
Philip Urban, Edoardo De Benedetti. (2007) Thrombosis: the last frontier of coronary stenting?. The Lancet 369:9562, 619-621
CrossRef221
Keeley, Ellen C., Hillis, L. David, . (2007) Primary PCI for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine 356:1, 47-54
Full Text222
Xavier García-Moll, Alfredo Bardají, Joaquín Alonso, Héctor Bueno. (2007) Actualización en cardiopatía isquémica 2006. Revista Española de Cardiología 60, 3-18
CrossRef223
Marcel AM Beijk, Jan J Piek. (2007) XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert Review of Medical Devices 4:1, 11-21
CrossRef224
Feng Zhang, Junbo Ge, Juying Qian, Bing Fan, Qibing Wang, Lei Ge, Xuebo Liu. (2007) Sirolimus-Eluting Stents in Real-World Patients With ST-Segment Elevation Acute Myocardial Infarction. International Heart Journal 48:3, 303-311
CrossRef225
W.H. Frishman. (2007) Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial. Yearbook of Medicine 2007, 344-347
CrossRef226
(2007) Sirolimus-eluting and paclitaxel-eluting stents for acute myocardial infarction. Nature Clinical Practice Cardiovascular Medicine 4:1, 10-11
CrossRef227
Jae Yeong Cho, Myung Ho Jeong, Ok Ja Choi, Seok Lee, Seon Young Jeong, In Soo Kim, Jung Sun Cho, Seung Hwan Hwang, Sun Ho Hwang, Nam Sik Yoon, Jae Youn Moon, Young Joon Hong, Ju Han Kim, Weon Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2007) Predictive Factors after Percutaneous Coronary Intervention in Young Patients with Acute Myocardial Infarction. Korean Circulation Journal 37:8, 373
CrossRef228
(2006) Drug-Eluting Stents in Primary PCI. New England Journal of Medicine 355:23, 2483-2486
Full Text229
Jacyntha A. Sterling. (2006) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 41:11, 1122-1128
CrossRef230
Laarman, Gerrit J., Suttorp, Maarten J., Dirksen, Maurits T., van Heerebeek, Loek, Kiemeneij, Ferdinand, Slagboom, Ton, van der Wieken, L. Ron, Tijssen, Jan G.P., Rensing, Benno J., Patterson, Mark, . (2006) Paclitaxel-Eluting versus Uncoated Stents in Primary Percutaneous Coronary Intervention. New England Journal of Medicine 355:11, 1105-1113
Full Text231
Van de Werf, Frans, . (2006) Drug-Eluting Stents in Acute Myocardial Infarction. New England Journal of Medicine 355:11, 1169-1170
Full Text
- Letters
